RT Journal Article
SR Electronic
T1 Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era
JF Cancer Epidemiology Biomarkers & Prevention
JO Cancer Epidemiol Biomarkers Prev
FD American Association for Cancer Research
SP 670
OP 674
DO 10.1158/1055-9965.EPI-13-1115
VO 23
IS 4
A1 Martino, Alessandro
A1 Campa, Daniele
A1 Jurczyszyn, Artur
A1 Martínez-López, Joaquín
A1 Moreno, María José
A1 Varkonyi, Judit
A1 Dumontet, Charles
A1 García-Sanz, Ramón
A1 Gemignani, Federica
A1 Jamroziak, Krzysztof
A1 Stępień, Anna
A1 Jacobsen, Svend E. Hove
A1 Andersen, Vibeke
A1 Jurado, Manuel
A1 Landi, Stefano
A1 Rossi, Anna Maria
A1 Lesueur, Fabienne
A1 Marques, Herlander
A1 Dudziński, Marek
A1 Wątek, Marzena
A1 Moreno, Victor
A1 Orciuolo, Enrico
A1 Petrini, Mario
A1 Reis, Rui Manuel
A1 Ríos, Rafael
A1 Sainz, Juan
A1 Vogel, Ulla
A1 Buda, Gabriele
A1 Vangsted, Annette Juul
A1 Canzian, Federico
YR 2014
UL http://cebp.aacrjournals.org/content/23/4/670.abstract
AB Background: Genetic background plays a role in multiple myeloma susceptibility. Several single-nucleotide polymorphisms (SNP) associated with genetic susceptibility to multiple myeloma were identified in the last years, but only a few of them were validated in independent studies. Methods: With the aim to conclusively validate the strongest associations so far reported, we selected the polymorphisms rs2227667 (SERPINE1), rs17501108 (HGF), rs3136685 (CCR7), rs16944 (IL1B), rs12147254 (TRAF3), rs1805087 (MTR), rs1800629 (TNF-α), rs7516435 (CASP9), rs1042265 (BAX), rs2234922 (mEH), and rs1801133 (MTHFR). We genotyped them in 1,498 multiple myeloma cases and 1,934 controls ascertained in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium, and meta-analyzed our results with previously published ones. Results: None of the selected SNPs were significantly associated with multiple myeloma risk (P value range, 0.055–0.981), possibly with the exception of the SNP rs2227667 (SERPINE1) in women. Conclusions: We can exclude that the selected polymorphisms are major multiple myeloma risk factors. Impact: Independent validation studies are crucial to identify true genetic risk factors. Our large-scale study clarifies the role of previously published polymorphisms in multiple myeloma risk. Cancer Epidemiol Biomarkers Prev; 23(4); 670–4. ©2014 AACR.